Skip to content

Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study

Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06455904
Acronym
PROTECT-07
Enrollment
156
Registered
2024-06-12
Start date
2024-05-30
Completion date
2027-01-13
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.

Detailed description

There will be two groups of patients after drawing lots using a process called randomization. The probability is one in two of being in the group participating in the training program, the other group following the standard treatment.

Interventions

The training program will be performed during 15 weeks, with one session per week.

Sponsors

Centre Paul Strauss
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

This is an interventional, randomized controlled, prospective, multicenter and adaptive study aimed at investigating the effect of a concentric pedaling training program carried out during (neo)adjuvant chemotherapy in addition to usual care.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Woman ≥ 18 years old * Stage I to III breast cancer * Patient currently planning (neo)adjuvant treatment combining anthracycline-cyclophosphamide and weekly paclitaxel (± trastuzumab) * Affiliation to a social security system * Able to speak, read and understand French

Exclusion criteria

* No prior chemotherapy treatment * Any known cardiac or vascular pathology * Contraindications to physical fitness assessment * Protected adult * Psychiatric, musculoskeletal or neurological problems * Pregnant or breastfeeding woman (NB: this population is already subject to a contraindication to (neo)adjuvant treatment. For women of childbearing age, a betaHCG dosage is already carried out systematically before the start of chemotherapy and information on the need for contraception throughout the chemotherapy period is provided before the start of treatment. As part of this study, only the presence of this test with a negative result at the start of chemotherapy will be checked. inclusion, if available).

Design outcomes

Primary

MeasureTime frameDescription
Overall exercise capacityAt week 18 (the end of chemotherapy treatment)To investigate the superiority of a concentric pedaling training program during (neo)adjuvant chemotherapy versus the absence of a training program in patients with early breast cancer. The overall exercise capacity is assessed by the 6-minute walk test (TDM6) between the two groups.

Secondary

MeasureTime frameDescription
Physiological variables associated with exercise capacity - cardiorespiratory capacityAt weeks 8.To examine the effects of the training program on VO2max.
Physiological variables associated with exercise capacity - muscle functionAt weeks 8.To examine the effects of the training program on maximal aerobic power determined as the lowest exercise intensity inducing a plateauing of O2 consumption during a maximum exercise test.
Physiological variables associated with exercise capacity - body compositionAt weeks 8.To examine the effects of the training program on lean mass, fat mass, muscle mass assessed by bioimpedancemetry.
Physiological variables associated with exercise capacity - muscle architectureAt weeks 8.To examine the effects of the training program on muscle thickness assessed by ultrasonography.
Psychosocial variables associated with exercise capacity - quality of lifeAt weeks 8.To examine the effects of the training program with the FACT-G questionnaire
Psychosocial variables associated with exercise capacity - fatigueAt weeks 8.To examine the effects of the training program with the FACIT-F questionnaire
Psychosocial variables associated with exercise capacity - appetite levelAt weeks 8.To examine the effects of the training program with the FAACT questionnaire

Countries

France

Contacts

CONTACTJoris MALLARD, PhD
j.mallard@icans.eu368767419
PRINCIPAL_INVESTIGATORBENDER Laura, MD

Institut de cancérologie Strasbourg Europe

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026